Data / Drug companies / Sodium-Glucose Cotransporter 2 Inhibitor
Sodium-Glucose Cotransporter 2 Inhibitor drugs: 12 drugs from 35 companies in the FDA NDC directory
Sodium-Glucose Cotransporter 2 Inhibitor is an FDA established pharmacologic class. The FDA National Drug Code Directory lists 135 products in this class from 35 companies, covering 12 drugs by generic name. The main marketing category is generic drugs (ANDA), and the newest product started marketing on October 1, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- 35Companies
- 135Products
- 12Drugs by generic name
Drugs in the Sodium-Glucose Cotransporter 2 Inhibitor class
Ranked by number of companies that list the drug.
| Drug | Products here | Companies listing it |
|---|---|---|
| Dapagliflozin | 52 | 26 |
| Dapagliflozin and metformin hydrochloride | 37 | 10 |
| Empagliflozin | 11 | 5 |
| Canagliflozin | 7 | 3 |
| Bexagliflozin | 3 | 2 |
| Canagliflozin and metformin hydrochloride | 8 | 1 |
| Empagliflozin and metformin hydrochloride | 4 | 1 |
| Empagliflozin, linagliptin, metformin hydrochloride | 4 | 1 |
| Empagliflozin, metformin hydrochloride | 4 | 1 |
| Empagliflozin and linagliptin | 2 | 1 |
| Sotagliflozin | 2 | 1 |
| Dapagliflozin and saxagliptin | 1 | 1 |
Companies with the most products in this class
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | 16 | tablet, extended release; tablet | New drug applications (NDA) | April 23, 2020 |
| A-S Medication Solutions | 13 | tablet, film coated | New drug applications (NDA) | April 6, 2026 |
| Janssen Pharmaceuticals, Inc. | 10 | tablet, film coated; tablet, film coated, extended release | New drug applications (NDA) | September 20, 2016 |
| AstraZeneca Pharmaceuticals LP | 7 | tablet, film coated, extended release; tablet, film coated | New drug applications (NDA) | October 29, 2014 |
| Novadoz Pharmaceuticals LLC | 7 | tablet, film coated, extended release; tablet, film coated | Generic drugs (ANDA) | April 6, 2026 |
| Ascend Laboratories, LLC | 6 | tablet, film coated, extended release; tablet, film coated | Generic drugs (ANDA) | April 6, 2026 |
| Aurobindo Pharma Limited | 6 | tablet, film coated, extended release; tablet, film coated | Generic drugs (ANDA) | April 6, 2026 |
| Lupin Pharmaceuticals, Inc. | 6 | tablet, extended release; tablet | Generic drugs (ANDA) | April 17, 2026 |
| Macleods Pharmaceuticals Limited | 6 | tablet, extended release; tablet | Generic drugs (ANDA) | April 6, 2026 |
| Micro Labs Limited | 6 | tablet, film coated, extended release; tablet | Generic drugs (ANDA) | October 1, 2026 |
| Cardinal Health 107, LLC | 4 | tablet, film coated | New drug applications (NDA) | August 1, 2014 |
| Prasco Laboratories | 4 | tablet, film coated, extended release; tablet, film coated | Authorized generics (NDA) | January 3, 2024 |
| Golden State Medical Supply, Inc. | 3 | tablet, film coated, extended release | Generic drugs (ANDA) | March 16, 2026 |
| Sun Pharmaceutical Industries, Inc. | 3 | tablet, film coated, extended release | Generic drugs (ANDA) | April 6, 2026 |
| Ajanta Pharma USA Inc. | 2 | tablet | Generic drugs (ANDA) | April 6, 2026 |
| Alembic Pharmaceuticals Inc. | 2 | tablet, film coated | Generic drugs (ANDA) | April 6, 2026 |
| Alembic Pharmaceuticals Limited | 2 | tablet, film coated | Generic drugs (ANDA) | April 6, 2026 |
| Ani Pharmaceuticals, Inc. | 2 | tablet, film coated | Generic drugs (ANDA) | May 13, 2026 |
| Aphena Pharma Solutions - Tennessee, LLC | 2 | tablet, film coated | New drug applications (NDA) | August 1, 2014 |
| Apotex Corp. | 2 | tablet, film coated | Generic drugs (ANDA) | April 8, 2026 |
| AvKARE | 2 | tablet, film coated | Generic drugs (ANDA) | May 25, 2026 |
| Biocon Pharma Inc. | 2 | tablet, film coated | Generic drugs (ANDA) | May 1, 2026 |
| Cipla USA Inc. | 2 | tablet, film coated | Generic drugs (ANDA) | April 6, 2026 |
| Florida Pharmaceutical Products, LLC | 2 | tablet | Generic drugs (ANDA) | April 6, 2026 |
| Lexicon Pharmaceuticals, Inc. | 2 | tablet | New drug applications (NDA) | May 26, 2023 |
| Redpharm Drug | 2 | tablet; tablet, film coated | Generic drugs (ANDA) | April 6, 2026 |
| Sandoz Inc | 2 | tablet, film coated | Generic drugs (ANDA) | April 6, 2026 |
| Teva Pharmaceuticals, Inc. | 2 | tablet, film coated | Generic drugs (ANDA) | April 8, 2026 |
| TheracosBio, LLC | 2 | tablet | New drug applications (NDA) | March 19, 2024 |
| Zydus Lifesciences Limited | 2 | tablet | Generic drugs (ANDA) | April 6, 2026 |
| Zydus Pharmaceuticals USA Inc. | 2 | tablet | Generic drugs (ANDA) | April 6, 2026 |
| Bryant Ranch Prepack | 1 | tablet, film coated | Authorized generics (NDA) | January 3, 2024 |
| Bryant Ranch Prepack | 1 | tablet, film coated | Generic drugs (ANDA) | April 8, 2026 |
| Golden State Medical Supply, Inc. | 1 | tablet | Authorized generics (NDA) | January 20, 2023 |
| Remedyrepack Inc. | 1 | tablet, film coated | New drug applications (NDA) | April 23, 2026 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated | 62 | 45.9% |
| Tablet, film coated, extended release | 33 | 24.4% |
| Tablet | 24 | 17.8% |
| Tablet, extended release | 16 | 11.9% |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.